| Revista: | Memorias do Instituto Oswaldo Cruz |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000437055 |
| ISSN: | 0074-0276 |
| Autores: | Biembengut, Isis Venturi1 Souza, Tatiana de Arruda Campos Brasil de1 |
| Instituciones: | 1Fundacao Oswaldo Cruz, Instituto Carlos Chagas, Curitiba, Parana. Brasil |
| Año: | 2020 |
| Volumen: | 115 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Nota breve o noticia |
| Enfoque: | Experimental, aplicado |
| Resumen en inglés | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection depends on viral polyprotein processing, catalysed by the main proteinase (Mpro). The solution of the SARS-CoV-2 Mpro structure allowed the investigation of potential inhibitors. This work aims to provide first evidences of the applicability of commercially approved drugs to treat coronavirus disease-19 (COVID-19). We screened 4,334 compounds to found potential inhibitors of SARS-CoV-2 replication using an in silico approach. Our results evidenced the potential use of coagulation modifiers in COVID-19 treatment due to the structural similarity of SARS-CoV-2 Mpro and human coagulation factors thrombin and Factor Xa. Further in vitro and in vivo analysis are needed to corroborate these results |
| Disciplinas: | Medicina |
| Palabras clave: | Química farmacéutica, COVID-19, SARS-CoV-2, Proteasas, Coagulación |
| Keyword: | Medicinal chemistry, Proteases, Coagulation, COVID-19, SARS-CoV-2 |
| Texto completo: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
